Liang QJ, Long QQ, Tian FQ, Su QY, Zhu XY, Long XD. Tissue inhibitor of metalloproteinase-3 expression affects clinicopathological features and prognosis of aflatoxin B1-related hepatocellular carcinoma. World J Hepatol 2024; 16(8): 1131-1144 [PMID: 39221097 DOI: 10.4254/wjh.v16.i8.1131]
Corresponding Author of This Article
Xi-Dai Long, MD, PhD, Professor, Research Scientist, Clinicopathological Diagnosis and Research Center, The Affiliated Hospital of Youjiang Medical University for Nationalities, No. 18 Zhongshan Road, Baise 533000, Guangxi Zhuang Autonomous Region, China. sjtulongxd@ymun.edu.cn
Research Domain of This Article
Gastroenterology & Hepatology
Article-Type of This Article
Observational Study
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Table 2 Clinical pathological features of hepatocellular carcinoma according to tissue inhibitor of metalloproteinase-3 expression
Variable
LTE
HTE
P value
n
Percentage (%)
n
Percentage (%)
Total
89
100.0
93
100.0
Age (years)
0.78
< 49
47
52.8
51
54.8
≥ 49
42
47.2
42
45.2
Gender
0.18
Male
70
78.7
65
69.9
Female
19
21.3
28
30.1
Race
0.89
Han
44
49.4
45
48.4
Others
45
50.6
48
51.6
Smoking
0.38
No
70
78.7
68
73.1
Yes
19
21.3
25
26.9
Drinking
0.50
No
68
76.4
67
72.0
Yes
21
23.6
26
28.0
HBsAg
0.13
Negative
26
29.2
37
39.8
Positive
63
70.8
56
60.2
Anti-HCV
0.47
Negative
71
79.8
78
83.9
Positive
18
20.2
15
16.1
AFP
4.66 × 10-13
Negative
8
9.0
56
60.2
Positive
81
91.0
37
39.8
Tumor size
2.54 × 10-4
≤ 5 cm
16
18.0
40
43.0
> 5 cm
73
82.0
53
57.0
ES grade
3.84 × 10-4
Low
34
38.2
60
64.5
High
55
61.8
33
35.4
TNM stage
1.18 × 10-4
I
6
6.7
24
25.8
II
35
39.3
43
46.2
III
48
53.9
26
28.0
Liver cirrhosis
0.14
No
32
36.0
24
25.8
Yes
57
64.0
69
74.2
MVD
2.97 × 10-3
Low
34
38.2
56
60.2
High
55
61.8
37
39.8
PVTT
2.32 × 10-5
Negative
49
55.1
78
83.9
Positive
40
44.9
15
16.1
MVI
2.99 × 10-4
Negative
45
50.6
71
76.3
Positive
44
49.4
22
23.7
Table 3 The risk effects of tissue inhibitor of metalloproteinase-3 expression in the cancerous tissues on the clinicopathological features of hepatocellular carcinoma
Table 6 Effects of aflatoxin B1 exposure and tissue inhibitor of metalloproteinase-3 expression on survival of patients with aflatoxin B1-related hepatocellular carcinoma
Table 7 Mulvariable Cox proportional hazard regression analysis for survival
OS
RFS
Variable
HR (95%CI)
P value
HR (95%CI)
P value
AFP, positive vs negative
2.85 (1.96-4.15)
5.06 × 10-8
2.48 (1.64-3.73)
1.44 × 10-5
AFB1 exposure, high vs low
2.92 (1.99-4.27)
3.71 × 10-8
3.23 (2.12-4.94)
5.78 × 10-8
Tumor size (cm), > 5 vs ≤ 5
2.93 (1.99-4.31)
4.53 × 10-8
2.79 (1.83-4.25)
2.00 × 10-6
ES grade, III-IV vs I-II
1.81 (1.29-2.55)
6.19 × 10-4
1.63 (1.12-2.37)
0.01
TNM stage, II vs I
1.61 (1.02-2.42)
0.03
1.75 (1.04-2.45)
0.02
TNM stage, III vs I
6.22 (3.70-10.48)
6.21 × 10-12
4.43 (2.54-7.71)
1.47 × 10-7
MVD, positive vs negative
2.88 (2.05-4.04)
1.07 × 10-9
3.34 (2.29-4.89)
4.71 × 10-10
PVTT, positive vs negative
2.30 (1.59-3.32)
8.73 × 10-6
2.34 (1.60-3.42)
1.16 × 10-5
MVI, positive vs negative
2.48 (1.74-3.54)
5.63 × 10-7
2.44 (1.68-3.53)
2.42 × 10-6
TIMP3, LTE vs HTE
2.85 (2.04-4.00)
1.17 × 10-9
2.26 (1.57-3.26)
1.26 × 10-5
Table 8 Correlation between aflatoxin B1 exposure and tissue inhibitor of metalloproteinase-3 expression in hepatocellular carcinoma
Low AFB1 exposure
High AFB1 exposure
r
P value
n
Percentage (%)
n
Percentage (%)
LTE
27
36.0
62
57.9
-0.216
0.003
HTE
48
64.0
45
42.1
Citation: Liang QJ, Long QQ, Tian FQ, Su QY, Zhu XY, Long XD. Tissue inhibitor of metalloproteinase-3 expression affects clinicopathological features and prognosis of aflatoxin B1-related hepatocellular carcinoma. World J Hepatol 2024; 16(8): 1131-1144